Multidrug resistant tuberculosis

BMJ. 2015 Feb 26:350:h882. doi: 10.1136/bmj.h882.

Authors

James Millard¹, Cesar Ugarte-Gil², David A J Moore³

Affiliations

¹ Brighton and Sussex Medical School, Brighton, UK.
² Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
³ TB Centre, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK David.moore@lshtm.ac.uk.

PMID: 25721508
DOI: 10.1136/bmj.h882

No abstract available

Publication types

Review

MeSH terms

Antitubercular Agents / therapeutic use*
Drug Administration Schedule
Drug Therapy, Combination
Forecasting
Genotype
Global Health
Humans
Isoniazid / therapeutic use
Microbial Sensitivity Tests
Palliative Care
Phenotype
Prognosis
Public Health
Rifampin / therapeutic use
Risk Factors
Tuberculosis, Multidrug-Resistant / diagnosis
Tuberculosis, Multidrug-Resistant / drug therapy*
Tuberculosis, Multidrug-Resistant / mortality

Substances

Antitubercular Agents
Isoniazid
Rifampin